Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)
Study Details
Study Description
Brief Summary
Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to determine the bioequivalence of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Healthy volunteers, 18-55 years of age, selected from the Egyptian population fulfilling the selection criteria. 24 healthy subjects will participate in the study. All dosed subject samples will be analyzed and their data will be included in the final study report Primary Pharmacokinetic Parameters: Cmax ,AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for log transformed (with the 90% confidence intervals) and untransformed data of Cmax,, AUC0→t and AUC0→∞and for untransformed data of Ke, tmax and t1/2e.
The confidence intervals of logarithmically transformed Test/Reference ratios for AUC0→t, AUC0→∞and Cmax to be within 80.00-125.00%.
A comprehensive final report will be issued upon the completion of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: T test 1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water. |
Drug: Bravamax 200 mg (Modafinil)
Test drug
Other Names:
|
| Active Comparator: R Reference 1 tablet contains 200 mg Modafinil administrated according to a randomization scheme with 240 ml of water. |
Drug: Vigil 200 mg (Modafinil)
Reference drug
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Cmax [Up to 72 hours post dose in each treatment period]
to measure the maximal measured plasma concentration
Secondary Outcome Measures
- Tmax [Up to 72 hours post dose in each treatment period]
time of the maximum plasma concentration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy male or female, age 18 to 55 years, inclusive.
-
Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI) which is between (18.5-30.0).
-
Medical demographics without evidence of clinically significant deviation from normal medical condition, eg: no history of heart, liver, kidney, gastrointestinal, nervous system, or metabolic abnormalities.
-
Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
-
Females should be on a suitable birth control method.
-
Fully informed subjects that consented to participate in the study.
Exclusion Criteria:
-
Subjects with known allergy to the products tested.
-
Subjects who meet any of the contraindications to the administration of Modafinil.
-
Subjects that do not agree not to consume alcohol-containing beverages and foods for 48 hours before dosing and throughout the period of sample collection.
-
Heavy smokers.
-
Female subjects who were pregnant or nursing.
-
Acute infection within one week preceding first study drug administration.
-
History of drug or alcohol abuse.
-
Subject does not comply with the stated instruction of not taking any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
-
Subject is on a special diet (for example subject is vegetarian).
-
Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
-
Subject does not agree not to consume any beverages or foods containing grapefruit 14 days prior to first study drug administration until the end of the study.
-
Subject has a family history of severe diseases which have direct impact on the study.
-
Participation in a bioequivalence study or in a clinical study within the last 8 weeks before first study drug administration.
-
Subject intends to be hospitalized within 3 months after first study drug administration.
-
Subjects who have blood donated or lost more than 500 mL blood within 3 months prior to the study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Genuine Research Center GRC | Cairo | Egypt | 11757 |
Sponsors and Collaborators
- Genuine Research Center, Egypt
- Chemipharm Pharmaceutical Industries, Egypt
Investigators
- Study Director: Ahmed Elshafeey, Ph.D. Pharma, Genuine Research Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- Description: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) The European Agency for the Evaluation of Medicinal Products (EMEA) May 1997
- Note for Guidance on Clinical Safety Data Management; Definitions And Standards for Expedited Reporting (CPMP/ICH/377/95) The European Agency for the Evaluation of Medicinal Products (EMEA) June 1995.
Publications
- Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353. Erratum In: J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):101.
- Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.
- GRC/1/22/1004